Abbott Laboratories (ABT) Other Accumulated Expenses (2009 - 2026)

Abbott Laboratories has reported Other Accumulated Expenses for 18 years, with the latest figure at $6.9 billion in Q2 2026.

• Quarterly Other Accumulated Expenses rose 21.85% year-over-year to $6.9 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $6.9 billion (up 21.85% YoY) and the FY2025 annual result came in at $5.8 billion, up 13.01% from the prior year.
• Other Accumulated Expenses grew to $6.9 billion in Q2 2026 per ABT's latest filing, from $6.4 billion in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $6.9 billion in Q2 2026 and troughed at $5.1 billion in Q2 2024.
• A 5-year average of $5.6 billion and a median of $5.5 billion in 2022 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2024 and 2026: Other Accumulated Expenses declined 9.34% in 2024, then grew 21.85% in 2026.
• Over 5 years, Other Accumulated Expenses stood at $5.8 billion in 2022, then declined by 7.24% to $5.4 billion in 2023, then dropped by 5.15% to $5.1 billion in 2024, then climbed by 13.01% to $5.8 billion in 2025, then increased by 18.58% to $6.9 billion in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $6.9 billion, $6.4 billion, and $5.8 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.